SGLT2 inhibitors did not reduce the risk for adverse liver outcomes more than DPP-4 inhibitors in patients with type 2 diabetes and metabolic dysfunction–associated steatotic liver disease.

For HHF, GLP1-RAs showed an IRR of 0.81 and SGLT2 inhibitors showed an IRR of 0.60 compared with DPP-4 inhibitors.

The EMPRISE real-world evidence study involves nearly 382,000 people with type 2 diabetes from 12 countries providing a comprehensive clinical picture of empagliflozin in treating people with type ...

Researchers noted fDPP-4 discriminated clinical activity from remission with areas under the curve of 0.8 (95% CI, 0.68-0.93) and 0.76 (95% CI, 0.58-0.94) in patients with UC and CD, respectively.

Most patients in the DPP-4 cohort received sitagliptin (94.6%), although saxagliptin and vildagliptin were also prescribed in 5.4% and less than 0.1% of patients, respectively.

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type ...

In the study, empagliflozin demonstrated a 22% relative risk reduction in all-cause hospitalizations vs DPP-4 inhibitors after a mean follow-up of 5.4 months.

The rate difference was −5.78 per 1,000 person-years for GLP-1 RA users versus DPP-4i users (hazard ratio, 0.90; 95 percent confidence interval, 0.82 to 0.98).